Phosphoserine containing compositions for immune tolerance induction
Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.
1. A method for inducing immune tolerance to a target antigen in an individual comprising:
a) providing to the individual a first regimen of multiple administrations over a period of at least 6 weeks of a first composition comprising liposomes, wherein the liposomes comprise phosphatidylcholine (PC) and lyso-phosphatidylserine (lyso-PS), wherein the ratio of PC to lyso-PS is from 90:10 to 60:40, and wherein the liposomes are complexed to a target antigen; and
b) while continuing the first regimen, providing to the individual a second regimen of one or more administrations of a second composition comprising the antigen free of liposomes.
2. The method of claim 1 , wherein the second regimen is started at least 4 weeks after the start of the first regimen.
3. The method of claim 1 , wherein the liposomes of the first composition comprise PC:lyso-PS in a ratio of 85:15 to 70:30.
4. The method of claim 1 , wherein the PC is dimyristoyl-sn-glycero-3 phosphatidylcholine (DMPC).
5. The method of claim 1 , wherein the acyl chain in lyso-PS is oleic acid.
6. The composition of claim 1 , wherein the target antigen is a therapeutic protein, a diagnostic protein, a self-antigen, a neo antigen, or an allergen.
7. The method of claim 1 , wherein the regimen for administration for the first composition continues over at least 9 weeks before the start of the second regimen.
8. The method of claim 1 , wherein the multiple administration of the first composition are carried out weekly.
9. A method for inducing immune tolerance to a target antigen in an individual comprising:
a) providing to the individual a first regimen of multiple administrations over a period of at least 6 weeks of a first composition comprising liposomes, wherein the liposomes comprise phosphatidylcholine (PC) and lyso-phosphatidylserine (lyso-PS), wherein the ratio of PC to lyso-PS is from 90:10 to 60:40, and wherein the liposomes are complexed to a target antigen; and
b) while continuing the first regimen, providing to the individual a second regimen of one or more administrations of a second composition comprising the antigen and liposomes which do not contain lyso-PS,
wherein the second regimen is started at least 4 weeks after the start of the first regimen.